Axiogenesis Cor.At mESC cardiomyocytes

Monday, 21 June, 2010 | Supplied by: Lonza Australia Pty Ltd



Embryonic stem cell-derived cardiomyocytes have many of the phenotypic properties of primary cardiomyocytes and show great potential to model human diseases. The Cor.At cells are cardiomyocytes derived from transgenic mouse embryonic stem cells and are available cryopreserved in ampoules.

The cells are highly pure with ampoules containing 99% cardiomyocytes. Their minimal lot-to-lot variation is claimed to give consistent performance and the standardised production process ensures stable supply.

The cardiomyocytes are a good predictive model with relevant background including all important ion channels well characterised.

They are suitable for applications including: electrophysiology (patch clamp, microelectrode arrays, Ca2+ flux analysis), non-arrhythmic cardiotoxicity (cell viability, label-free analysis, troponin release), drug profiling and target discovery (hypertrophy, gene expression, transfection, tissue engineering).

Online: www.lonza.com
Phone: 03 9550 0883
Related Products

AdipoGen Life Sciences tubulin products for neurodegeneration research

AdipoGen Life Sciences offers a broad range of microtubule research solutions. This includes...

SYnAbs monoclonal antibodies

SYnAbs produces innovative monoclonal antibodies against poor immunogenic compounds and complex...

Merck VirusExpress Lentiviral Production Platform

The platform helps to overcome lentiviral production challenges and can reduce process...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd